Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

1,904

Participants

Timeline

Start Date

April 1, 2006

Primary Completion Date

October 1, 2009

Study Completion Date

February 24, 2012

Conditions

Bone Metastases

Interventions

DRUG

zoledronic acid

Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC

BIOLOGICAL

denosumab

Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes